Loading
Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti.
Zhang founded GenScript in New Jersey in 2002 and moved it to Nanjing; Legend Biotech, spun out in 2014, developed the llama-derived BCMA CAR-T LCAR-B38M (LEGEND-2), partnered it with Janssen in 2017 and listed on Nasdaq in 2020; ciltacabtagene autoleucel was approved by the FDA in 2022 and the NMPA in 2024. He stepped back from executive roles in 2021.
Shares Legend Biotech, CARTITUDE-1, Ciltacabtagene autoleucel.
Shares CARTITUDE-1, Ciltacabtagene autoleucel.
Shares Legend Biotech, LEGEND-2, Ciltacabtagene autoleucel.
Shares Legend Biotech, Ciltacabtagene autoleucel.
Shares Legend Biotech, Ciltacabtagene autoleucel.
Shares Legend Biotech, Ciltacabtagene autoleucel.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/